IP Library Granted Patent US 8,883,158
Granted Patent B2
US 8,883,158 · App. 13/557,562 · Granted Nov 11, 2014

Compositions and methods for antibodies targeting complement protein C5

Inventors: Beate Diefenbach-Streiber (Windach, DE); Adina Eberth (Munich, DE); Braydon Charles Guild (Concord, MA); Yong-In Kim (Westborough, MA); Michael Roguska (Ashland, MA); Igor Splawski (Winchester, MA)
Assignee: Novartis AG
C07K16/18C07K2317/565C07K2316/96C07K2317/55C07K2317/21C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,158
App. No.
13/557,562
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

Claims (18)

1. An isolated antibody or an antigen binding fragment thereof that specifically binds to a human complement C5 protein, said antibody or antigen binding fragment thereof comprising a HCDR1 sequence comprising the sequence of SEQ ID NO: 17, a HCDR2 sequence comprising the sequence of SEQ ID NO: 18, a HCDR3 sequence comprising the sequence of SEQ ID NO: 19, a LCDR1 sequence comprising the sequence of SEQ ID NO: 20, a LCDR2 sequence comprising the sequence of SEQ ID NO: 21, and a LCDR3 sequence comprising the sequence of SEQ ID NO: 22.

2. The antibody of claim 1 , wherein said antibody is a monoclonal antibody.

3. The antibody of claim 2 , wherein said antibody is a human or humanized antibody.

4. The antibody of claim 2 , wherein said antibody is a chimeric antibody.

5. The antibody of claim 2 , wherein said antibody comprises a human heavy chain constant region and a human light chain constant region.

6. The antibody of claim 2 , wherein said antibody is a single chain antibody.

7. The antibody of claim 2 , wherein said antibody is a Fab fragment.

8. The antibody of claim 2 , wherein said antibody is a scFv.

9. The antibody of claim 2 binds to both human complement C5 and cynomolgus complement C5.

10. The antibody of claim 2 is an IgG isotype.

11. The antibody of claim 2 , wherein said antibody comprises a framework in which amino acids have been substituted into the antibody framework from the respective human VH or VL germline sequences.

12. The antibody, or an antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 23.

13. The antibody, or an antigen binding fragment thereof of claim 1 , comprising a light chain variable region having at least 95% sequence identity to SEQ ID NO: 24.

14. The antibody or antigen binding fragment thereof of claim 12 , further comprising a light chain variable region having at least 95% sequence identity to SEQ ID NO: 24.

15. The antibody, or an antigen binding fragment thereof of claim 1 , comprising a heavy chain having at least 95% sequence identity to SEQ ID NO: 25 wherein said antibody binds to human complement C5 protein.

16. The antibody, or an antigen binding fragment thereof of claim 1 , comprising a light chain having at least 95% sequence identity to SEQ ID NO: 26, wherein said antibody binds to human complement C5 protein.

17. The antibody of claim 15 , or an antigen binding fragment thereof, further comprising a light chain having at least 95% sequence identity to SEQ ID NO: 26.

18. A pharmaceutical composition comprising an antibody of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2012
From: DIEFENBACH-STREIBER, BEATE; EBERTH, ADINA; GUILD, BRAYDON CHARLES; KIM, YONG-IN; ROGUSKA, MICHAEL; SPLAWSKI, IGOR
To: NOVARTIS AG
Reel/Frame 028817/0204 →
Continuity (3)
Continuation 12535205 · Aug 4, 2009
Provisional Application 61086355 · Aug 5, 2008
Related Publication 20130064836A1 · Mar 14, 2013